Shares of Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, plunged 7.95% in after-hours trading on November 4, 2024, following the release of the company's third-quarter financial results.
While Glaukos reported record net sales of $96.7 million, representing a 24% year-over-year increase and beating analysts' estimates, the company's profitability was hampered by higher operating expenses and charges related to debt refinancing.
Glaukos' net loss for the third quarter widened to $21.4 million, or $0.39 per diluted share, compared to a net loss of $30.4 million, or $0.63 per diluted share, in the same period last year. The company's selling, general and administrative expenses rose 18% to $64.0 million, while research and development expenses increased 4% to $34.7 million.
Furthermore, Glaukos incurred charges associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million.
Despite the disappointing bottom-line results, Glaukos raised its full-year 2024 net sales guidance to a range of $377 million to $379 million, up from the previous range of $370 million to $376 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.